Improving decision-making in early breast cancer: Who to treat and how?

Breast Cancer Research and Treatment

Volumn 112, Issue SUPPL. 1, 2008, Pages 15-24

  Llombart Cussac, Antonio ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Chemotherapy; Early breast cancer; Predictive markers; Prognosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CLINICAL PRACTICE; EARLY CANCER; HUMAN; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT PLANNING;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DECISION MAKING; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 58249110803     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0234-8     Document Type: Article

References (73)

1. A Goldhirsch WC Wood RD Gelber 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 10.1093/annonc/mdm271
2. R Arriagada LE Rutqvist H Johansson 2008 Predicting distant dissemination in patients with early breast cancer Acta Oncol 3 1 9 10.1080/02841860701829661
3. EA Rakha ME El-Sayed AH Lee 2008 Prognostic significance of Nottingham histological grade in invasive breast carcinoma J Clin Oncol 26 3153 3158 10.1200/JCO.2007.15.5986
4. C Sotiriou P Wirapati S Loi 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262 272
5. AH Lee IO Ellis 2008 The nottingham prognostic index for invasive carcinoma of the breast Pathol Oncol Res 14 113 115
6. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women Lancet 339 71 85
7. PE Lønning S Knappskog V Staalesen 2007 Breast cancer prognostication and prediction in the postgenomic era Ann Oncol 18 1293 1306 10.1093/annonc/mdm013
8. LJ van't Veer H Dai MJ van de Vijver 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a
9. Y Wang JGM Klijn Y Zhang 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 671 679
10. AJ Minn Y Kang I Serganova 2005 Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors J Clin Invest 115 44 55
11. M Smid Y Wang JG Klijn 2006 Genes associated with breast cancer metastatic to bone J Clin Oncol 24 2261 2267 10.1200/JCO.2005.03.8802
12. HP Dhakal B Naume M Synnestvedt 2008 Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination Clin Cancer Res 14 2341 2350
13. VY Sohn ZM Arthurs JA Sebesta 2008 Primary tumor location impacts breast cancer survival Am J Surg 195 641 644 10.1016/j.amjsurg.2007.12.039
14. K Annecke M Schmitt U Euler 2008 uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial Adv Clin Chem 45 31 45 10.1016/S0065-2423(07)00002-9
15. AS Kumar V Bhatia IC Henderson 2005 Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective Breast Cancer Res Treat 7 274 275
16. JL Jones 2006 Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective Breast Cancer Res 8 204 10.1186/bcr1397
17. PE Lønning T Sorlie AL Borresen-Dale 2005 Genomics in breast cancer-therapeutic implications Nat Clin Pract Oncol 2 26 33 10.1038/ncponc0072
18. A Goldhirsch JH Glick RD Gelber 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326
19. E Arriola SM Rodriguez-Pinnilla MB Lambros 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 181 189 10.1007/s10549-006-9492- 5
20. MC Cheang M van de Rijm TO Nielsen 2008 Gene expression profiling of breast cancer Annu Rev Pathol 3 67 97 10.1146/annurev.pathmechdis.3.121806. 151505
21. M Kaufmann GN Hortobagyi A Goldhirsch 2006 Recommendations from an international expert panel on use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 10.1200/JCO.2005.02.6187
22. B Fisher A Brown E Mamounas 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483 2493
23. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
24. G Bonadonna P Valagussa C Brambilla 1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 93 100
25. AU Buzdar R Valerom RL Theriault 2003 Pathological complete response to chemotherapy is related to hormone receptor status Breast Cancer Res Treat 83 569a (Abstract 302)
26. L Gianni J Baselga W Eiermann 2005 European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) Proc Am Soc Clin Oncol 23 7s (Astract 513)
27. HD Bear S Anderson RE Smith 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019 2027 10.1200/JCO.2005.04.1665
28. W Eiermann S Paepke J Appfelstaedt 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527 1532 10.1023/A:1013128213451
29. IE Smith M Dowsett SR Ebbs 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116 10.1200/JCO.2005.04.005
30. VF Semiglazov V Semiglazov V Ivanov 2004 The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer Proc Am Soc Clin Oncol 22 517 (abstract 519)
31. V Semiglazov A Kletsel V Semiglazov 2005 Exemestane vs tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) Proc Am Soc Clin Oncol 23 11s (abstract 530)
32. BC Pestalozzi E Luporsi-Gely LM Jost 2005 ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer Ann Oncol 16 suppl 1 i7 i9 10.1093/annonc/mdi825
33. U Veronesi N Cascinelli L Mariani 2002 Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer N Engl J Med 347 1227 1232 10.1056/NEJMoa020989
34. IE Smith GM Ross 2004 Breast radiotherapy after lumpectomy-no longer always necessary N Engl J Med 351 1021 1023 10.1056/NEJMe048173
35. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2087 2106
36. B Fisher S Anderson CK Redmond 1995 Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med 333 1456 1461 10.1056/NEJM199511303332203
37. AW Fyles DR McCready LA Manchul 2004 Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer N Engl J Med 351 963 970 10.1056/NEJMoa040595
38. KS Hughes LA Schnaper D Berry 2004 Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer N Engl J Med 351 971 977 10.1056/NEJMoa040587
39. U Veronesi E Marubini L Mariani 2001 Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial Ann Oncol 12 997 1003 10.1023/A:1011136326943
40. J Ragaz IA Olivotto JJ Spinelli 2005 Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial J Natl Cancer Inst 97 116 126
41. U Veronesi G Gatti A Luini 2003 Intraoperative radiation therapy for breast cancer: technical notes Breast J 9 106 112 10.1046/j.1524-4741.2003. 09208.x
42. RR Patel RK Das 2006 Image-guided breast brachytherapy: an alternative to whole-breast radiotherapy Lancet 7 407 415 10.1016/S1470-2045(06)70692-1
43. L Biganzoli WM Claudino M Pestri 2007 Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand? Crit Rev Oncol Hematol 62 1 8 10.1016/j.critrevonc.2006.10.004
44. DA Berry C Cirrincione IC Henderson 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 10.1001/jama.295.14.1658
45. M Colozza E De Azambuja F Cardoso 2006 Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era Oncologist 11 111 125 10.1634/theoncologist.11-2-111
46. A Goldhirsch A Coates R Gelber St Gallen Expert Panel Members 2006 First-select the target: better choice of adjuvant treatments for breast cancer patients Ann Oncol 17 1772 1776 10.1093/annonc/mdl398
47. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
48. K Albain W Barlow F O'Malley 2004 Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (INT-0100, SWOG-8814): concurrent (CAFT) vs sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) vs. T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone PgR receptor-positive breast cancer Breast Cancer Res Treat 84 132 Abstract 37
49. KS Albain 2005 Do all patients with endocrine-responsive early breast cancer need adjuvant chemotherapy before endocrine treatment? Breast 14 S9 S10 10.1016/S0960-9776(05)80026-8
50. F Andre K Broglio H Roche 2007 Estrogen receptor expression and efficacy of docetaxel in early breast cancer: a pooled analysis of 3,490 patients included in two randomized trials J Clin Oncol 25 12 S Abstract 537
51. HB Muss L Biganzoli DJ Sargent M Aapro 2007 Adjuvant therapy in the elderly: making the right decision J Clin Oncol 25 1870 1875 10.1200/JCO.2006.10.3457
52. S Paik G Tang S Shak 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726 3734 10.1200/JCO.2005.04.7985
53. J Juenger D Schellberg S Kraemer 2002 Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables Heart 87 235 241 10.1136/heart.87.3.235
54. ™ Breast Cancer V.2.2008. Available at http://www.nccn.org/professionals/physician-gls/ PDF/breast.pdf Last accessed 06 August 2008
55. EP Winer C Hudis HJ Burstein 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer J Clin Oncol 23 619 629 10.1200/JCO.2005.09.121
56. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462 10.1016/S0140-6736(05)67059-6
57. RC Coombes LS Kilburn CF Snowdon 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 10.1016/S0140-6736(07) 60200-1
58. A Howell J Cuzick M Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(05)74803-0
59. AS Coates A Keshaviah B Thürlimann 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492 10.1200/JCO.2006.08.8617
60. L Mauriac A Keshaviah M Debled 2007 Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Ann Oncol 18 859 867 10.1093/annonc/mdm001
61. A Brufsky WG Harker JT Beck 2007 Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 25 829 836
62. N Bundred I Campbell R Coleman 2006 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study) Eur J Cancer Suppl 4 48 (abstract 12)
63. M Caraglia D Santini M Marra 2006 Emerging anticancer molecular mechanisms of aminobisphosphonates Endocr Relat Cancer 13 7 26 10.1677/erc.1.01094
64. SP Jagdev RE Coleman CM Shipman A Rostami-H PI Croucher 2001 The bisphosphonate, ZA, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Br J Cancer 84 1126 1134 10.1054/bjoc.2001.1727
65. HL Neville-Webbe CA Evans RE Coleman I Holen 2006 Mechanisms of the synergistic interaction between the bisphosphonate ZA and the chemotherapy agent paclitaxel in breast cancer cells in vitro Tumour Biol 27 92 103 10.1159/000092489
66. BE Hillner JN Ingle RT Chlebowski 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042 4057 10.1200/JCO.2003.08.017
67. MS Aapro P Hadji A Brufsky 2007 Recommendations for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer Eur J Cancer Suppl 5 186 (abstract 2007)
68. N Wolmark J Wang E Mamounas 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 JNCI Monogr 30 96 102
69. JA van der Hage CJ van der Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
70. L Mauriac G MacGrogan A Avril 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 47 52 10.1023/A:1008337009350
71. SM Scholl A Fourquet B Asselain 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 Eur J Cancer 30A 645 652 10.1016/0959-8049(94)90537-1
72. P Broët SM Scholl A de la Rochefordière 1999 Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial Breast Cancer Res Treat 58 151 156 10.1023/A:1006339918798
73. A Makris TJ Powles SE Ashley 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179 1184 10.1023/A:1008400706949